Imeglimin attenuates liver fibrosis by inhibiting vesicular ATP release from hepatic stellate cells.

Intraperitoneal glucose tolerance test (ipGTT) at Week 16 showed a trend toward improved glucose tolerance in the imeglimin treatment group compared to the Sal or TAA group, suggesting that imeglimin administration may have exerted a clinically meaningful effect (Fig. 1D ).

also in 53,322 other papers